Cleaning procedures at Getinge's N.J. plant trigger FDA warning

08/25/2010 | Clinica (subscription required)

The FDA issued a warning letter to Getinge regarding issues with its vascular graft cleaning procedures at its production plant in Wayne, N.J., and a discrepancy related to the 2006 recall of the Hemashield vascular graft. Getinge CEO Johan Malmquist said the warning would not affect the production and marketing of its products at the facility, and that the company hopes to resolve the issues by the end of the year.

View Full Article in:

Clinica (subscription required)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park